The FDA has approved Boehringer Ingelheim’s Spevigo (spesolimab) for generalized pustular psoriasis (GPP) flares in adults, making it the first drug approved for this indication.
https://www.pharmalive.com/wp-content/uploads/2022/09/BioSpaceBoehringerIngelheim9-2-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-09-02 11:48:372022-09-02 11:48:37Boehringer bags first FDA approval for rare skin disease
